Glow Lifetech (GLOW) investor relations material

Executive summary

• Achieved record Q1 2026 revenue of $643,519, up 35% year-over-year and 27% sequentially, marking the highest quarterly revenue to date.

• Gross profit rose 30% year-over-year to $413,259, with gross margin at 64% despite a slight decrease from 66% last year.

• EBITDA loss narrowed significantly to $6,971, a 90% improvement year-over-year, nearing breakeven.

• Expanded national footprint with new market entries and product launches, including entry into the Canadian medical cannabis channel.

Financial highlights

• Total expenses increased modestly by 4% year-over-year to $483,975, reflecting disciplined cost management.

• Cash used in operating activities rose 99% to $317,074, mainly due to working capital investments for growth.

• Cash balance increased 44% year-over-year to $1,590,927, with a working capital surplus of $1,855,233.

• Current ratio stood at 2.70x, indicating strong liquidity.

Outlook and guidance

• Management expects continued growth through national distribution expansion, product innovation, and operational efficiency.

• Focus remains on disciplined execution and capital-efficient growth to support long-term sustainable growth and shareholder value.